'''Ethyl loflazepate'''<ref>DE Patent 2012190</ref> (marketed under the brand names '''Meilax''', '''Ronlax''' and '''Victan''')<ref>{{cite journal |pmid=2904268 |date=Oct 1988 |last1=Ba |first1=BB |last2=Iliadis |last3=Durand |last4=Berger |last5=Cano |title=New approach in bioavailability study of two formulations of ethyl loflazepate |volume=38 |issue=10 |pages=1486–9 |issn=0004-4172 |journal=Arzneimittel-Forschung |first2=A |first3=A |first4=Y |first5=JP }}</ref><ref>{{cite journal |pmid=2574017 |year=1989 |last1=Ba |first1=BB |last2=Iliadis |last3=Cano |title=Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites |volume=17 |issue=6 |pages=633–46 |issn=0090-6964 |journal=Annals of Biomedical Engineering |doi=10.1007/BF02367467 |first2=A |first3=JP }}</ref><ref>{{cite web|url=http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html |title=Benzodiazepine Names |accessdate=2009-04-05 |publisher=non-benzodiazepines.org.uk |deadurl=yes |archiveurl=https://web.archive.org/web/20081208054743/http://www.non-benzodiazepines.org.uk/benzodiazepine-names.html |archivedate=2008-12-08 |df= }}</ref> is a drug which is a [[benzodiazepine]] derivative. It possesses [[anxiolytic]], [[anticonvulsant]], [[sedative]] and [[skeletal muscle relaxant]] properties.<ref>{{cite journal |pmid=6142848 |date=Nov 1983 |last1=Ueki |first1=S |last2=Watanabe |last3=Yamamoto |last4=Shibata |last5=Shibata |last6=Ohta |last7=Ikeda |last8=Kiyota |last9=Sato |title=Behavioral effects of ethyl loflazepate and its metabolites |volume=82 |issue=5 |pages=395–409 |issn=0015-5691 |journal=Nippon yakurigaku zasshi. Folia pharmacologica Japonica |url= |format= |doi=10.1254/fpj.82.395 |first2=S |first3=T |first4=S |first5=K |first6=H |first7=K |first8=Y |first9=Y  }}</ref> In animal studies it was found to have low toxicity, although in rats evidence of pulmonary phospholipidosis occurred with pulmonary foam cells developing with long-term use of very high doses.<ref>{{cite journal |pmid=6116677 |date=Oct 1981 |last1=Mazue |first1=G |last2=Berthe |last3=Newmann |last4=Brunaud |title=A toxicologic evaluation of ethyl fluclozepate (CM 6912) |volume=19 |issue=10 |pages=453–72 |issn=0174-4879 |journal=International journal of clinical pharmacology, therapy, and toxicology |first2=J |first3=AJ |first4=M }}</ref> Its elimination half-life is 51–103 hours.<ref>{{cite journal |pmid=6112027 |date=Nov 1980 |last1=Cautreels |first1=W |last2=Jeanniot |title=Quantitative analysis of CM 6912 (ethyl loflazepate) and its metabolites in plasma and urine by chemical ionization gas chromatography mass spectrometry. Application to pharmacokinetic studies in man |volume=7 |issue=11–12 |pages=565–71 |issn=0306-042X |journal=Biomedical Mass Spectrometry |doi=10.1002/bms.1200071124 |first2=JP }}</ref> Its mechanism of action is similar to other benzodiazepines. Ethyl loflazepate also produces an [[active metabolite]] which is stronger than the parent compound.<ref>{{cite journal |pmid=2861304 |date=Apr 1985 |last1=Sakai |first1=Y |last2=Namima |title=Inhibitory effect on 3H-diazepam binding and potentiating action on GABA of ethyl loflazepate, a new minor tranquilizer |volume=37 |issue=4 |pages=373–9 |issn=0021-5198 |journal=Japanese journal of pharmacology |url= |format= |doi=10.1254/jjp.37.373 |first2=M }}</ref> Ethyl loflazepate was designed to be a [[prodrug]] for [[descarboxyloflazepate]], its [[active metabolite]]. It is the active metabolite which is responsible for most of the pharmacological effects rather than ethyl loflazepate.<ref>{{cite journal |pmid=2866771 |year=1985 |last1=Chambon |first1=JP |last2=Perio |last3=Demarne |last4=Hallot |last5=Dantzer |last6=Roncucci |last7=Bizière |title=Ethyl loflazepate: a prodrug from the benzodiazepine series designed to dissociate anxiolytic and sedative activities |volume=35 |issue=10 |pages=1573–7 |issn=0004-4172 |journal=Arzneimittel-Forschung |url= |format= |first2=A |first3=H |first4=A |first5=R |first6=R |first7=K }}</ref> The main metabolites of ethyl loflazepate are descarbethoxyloflazepate, loflazepate and 3-hydroxydescarbethoxyloflazepate.<ref>{{cite journal |pmid=2864933 |year=1985 |last1=Davi |first1=H |last2=Guyonnet |last3=Sales |last4=Cautreels |title=Metabolism of ethyl loflazepate in the rat, the dog, the baboon and in man |volume=35 |issue=7 |pages=1061–5 |issn=0004-4172 |journal=Arzneimittel-Forschung |first2=J |first3=Y |first4=W }}</ref> Accumulation of the active metabolites of ethyl loflazepate are not affected by those with [[renal failure]] or impairment.<ref>{{cite journal |pmid=2714728 |year=1989 |last1=Ba |first1=BB |last2=Iliadis |last3=Durand |last4=Berger |last5=Necciari |last6=Cano |title=Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man |volume=3 |issue=1 |pages=11–7 |issn=0767-3981 |journal=Fundamental & clinical pharmacology |doi=10.1111/j.1472-8206.1989.tb00025.x |first2=A |first3=A |first4=Y |first5=J |first6=JP }}</ref> The symptoms of an [[overdose]] of ethyl loflazepate include [[sleepiness]], [[psychomotor agitation|agitation]] and [[ataxia]]. [[Hypotonia]] may also occur in severe cases. These symptoms occur much more frequently and severely in children.<ref>{{cite journal |vauthors=Pulce C, Mollon P, Pham E, Frantz P, Descotes J |title=Acute poisonings with ethyle loflazepate, flunitrazepam, prazepam and triazolam in children |journal=Vet Hum Toxicol |volume=34 |issue=2 |pages=141–3 |date=April 1992 |pmid=1354907 |doi= |url= |issn=0145-6296 |format=}}</ref> Death from therapeutic maintenance doses of ethyl loflazepate taken for 2 – 3 weeks has been reported in 3 elderly patients. The cause of death was [[asphyxia]] due to benzodiazepine toxicity.<ref>{{cite journal |pmid=15902983 |date=Mar 2005 |last1=Kamijo |first1=Y |last2=Hayashi |last3=Nishikawa |last4=Yoshimura |last5=Soma |title=Pharmacokinetics of the active metabolites of ethyl loflazepate in elderly patients who died of asphyxia associated with benzodiazepine-related toxicity |volume=29 |issue=2 |pages=140–4 |issn=0146-4760 |journal=Journal of analytical toxicology |first2=I |first3=T |first4=K |first5=K |doi=10.1093/jat/29.2.140}}</ref> High doses of the antidepressant fluvoxamine may potentiate the adverse effects of ethyl loflazepate.<ref>{{cite journal |pmid=11778459 |date=Dec 2001 |last1=Imanishi |first1=T |last2=Onozawa |last3=Hayashi |last4=Baba |title=Effects of fluvoxamine on both the desired anxiolytic effect and the adverse motor incoordination and amnesia induced by benzodiazepines |volume=118 |issue=6 |pages=403–10 |issn=0015-5691 |journal=Nippon yakurigaku zasshi. Folia pharmacologica Japonica |doi=10.1254/fpj.118.403 |first2=K |first3=A |first4=J }}</ref>
